Lotus Eye Hospital and Institute share price & results
- Jun 2026
- Jun 2026
South-India chain of super-specialty eye-care hospitals across Tamil Nadu and Kerala offering LASIK, cataract, cornea, retina and glaucoma surgery.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 17.1 | +26.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 17.3 | +6.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 0.61 | +13.0% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 0.27 | −1.1 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -18.47 | −14.3 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 14.09 | +5.6 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −7.1% 1Y
1Y: ₹117.98 on 24 Oct 2025 → ₹109.65. High ₹141.38 (29 Jan 2026), low ₹98.22 (30 Mar 2026).
- Previous close
- ₹113.56
- Market cap
- ₹240 Cr
- 52-week range
- ₹98.22 – ₹141.38
- One year
- −8.82%
- Return on equity (TTM to Jun 2026)
- 0.27%
Overview
- Symbol
- NSE:LOTUSEYE
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Lotus Eye Hospital and Institute Limited does
Based on the company's own presentations, annual report and earnings calls.
Lotus Eye Hospital and Institute Limited runs a network of super-specialty ophthalmology hospitals across Tamil Nadu and Kerala, providing surgical and non-surgical eye-care services such as refractive surgery (LASIK/SMILE), cataract surgery, corneal and retinal treatment, glaucoma surgery and ocuplasty. It earns revenue from patient treatment and surgical procedures delivered at its hospital centers. The company also runs an affiliated optometry training institute (Lotus Bausch & Lomb Institute of Optometry) and conducts free community eye-care camps and screening drives.
Segments
- Refractive surgery
- Cataract surgery
- Cornea treatment
- Retina treatment
- Glaucoma treatment
- Ocuplasty
- Eye care centers
- 9 (7 in Tamil Nadu, 2 in Kerala)
- Cities covered
- Coimbatore, Salem, Tirupur, Mettupalayam, Karur, Kochi, Mulanthuruthy
- Cumulative surgeries performed
- 2 Lakh+
- Cumulative procedures performed
- 10 Lakh+
- Cumulative eyes screened
- 1 Crore+
- Qualified staff
- 300+
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +13% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 12 | 12 | 14 | 13 | 14 | 14 | 17 |
| Expenses | 12 | 11 | 12 | 12 | 12 | 13 | 13 | 14 |
| Operating profit | 1 | 1 | -0 | 1 | 1 | 1 | 0 | 3 |
| Operating margin | 8.9% | 6.5% | −1.5% | 10.9% | 5.9% | 4.9% | 3.5% | 17.3% |
| Other income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 1 | 1 | -1 | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 0 | -0 | 1 | 1 | 0 | -0 | -0 | 1 |
| Tax rate | 9.1% | −44.2% | 70.2% | 24.7% | −71.4% | −29.7% | −33.3% | 39.6% |
| Net profit | 0 | -0 | 0 | 1 | 0 | -0 | -0 | 1 |
| EPS (₹ per share) | 0.05 | -0.12 | 0.12 | 0.26 | 0.06 | -0.13 | -0.15 | 0.29 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 48 | 50 | 54 |
| Expenses | 42 | 46 | 50 |
| Operating profit | 7 | 3 | 3 |
| Other income | 1 | 1 | 1 |
| Interest | 0 | 0 | 1 |
| Depreciation | 4 | 3 | 4 |
| Profit before tax | 4 | 1 | -0 |
| Net profit | 3 | 1 | 0 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 34 | 37 | 39 | 39 | 40 | 39 |
| Borrowings | 1 | 1 | 1 | 3 | 5 | 16 |
| Other liabilities | 6 | 5 | 6 | 6 | 6 | 7 |
| Total liabilities | 62 | 63 | 67 | 70 | 72 | 83 |
| Fixed assets | 44 | 44 | 49 | 54 | 55 | 66 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 18 | 19 | 18 | 16 | 16 | 17 |
| Total assets | 62 | 63 | 67 | 70 | 72 | 83 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 3 | 4 | 4 | 6 | 3 | 3 |
| Cash from investing | 0 | -4 | -2 | -5 | -6 | -14 |
| Cash from financing | -0 | -2 | -2 | -3 | -2 | 9 |
| Net cash flow | 3 | -1 | 0 | -2 | -5 | -2 |
| Free cash flow | 3 | -0 | 1 | 0 | -2 | -10 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 8 | 6 | 9 | 10 | 10 | 8 |
| Inventory days | 139 | 150 | 154 | 170 | 194 | 172 |
| Days payable | 221 | 231 | 173 | 184 | 170 | 146 |
| Cash conversion cycle | -74 | -75 | -11 | -4 | 33 | 34 |
| Working capital days | -24 | -16 | 9 | 6 | 0 | -12 |
| Return on capital employed | 3.9% | 7.9% | 10.3% | 7.1% | 3.0% | 1.4% |
| Dividend payout | 66.2% | 34.9% | 25.5% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Public hold 59.85% as of Jun 2026; institutions added 0.00 pts since Mar 2026.
- Promoters 40.14%
- Foreign institutions 0.00%
- Domestic institutions 0.02%
- Public 59.85%
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- +0.39 pp 2.66% held
- +0.27 pp 7.93% held
- +0.10 pp 1.42% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Lotus Eye Hospital and Institute Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 34.98% | unchanged | |
| 7.93% | +0.27 pp | |
| 4.84% | unchanged | |
| 4.67% | unchanged | |
| 4.53% | unchanged | |
| 3.92% | unchanged | |
| 2.75% | unchanged | |
| 2.66% | +0.39 pp | |
| 2.41% | unchanged | |
| 1.97% | unchanged | |
| 1.46% | unchanged | |
| 1.42% | +0.10 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Lotus Eye Hospital and Institute Limited
Free account: one company. Everything above stays public.
Write why you follow Lotus Eye Hospital and Institute Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Lotus Eye Hospital and Institute Limited
Guides on how to read this kind of business and the numbers that matter.